Alpha-Ketoglutarate and 5-HMF: A Potential Anti-Tumoral Combination against Leukemia Cells.

5-hydroxy-methyl-furfural (5-HMF) alpha-ketoglutarate (aKG) carbonylated proteins (CP) caspase activity human fibroblasts (HF-SAR) leukemia proliferation reactive oxygen and nitrogen species (RONS)

Journal

Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981

Informations de publication

Date de publication:
12 Nov 2021
Historique:
received: 09 10 2021
revised: 27 10 2021
accepted: 10 11 2021
entrez: 27 11 2021
pubmed: 28 11 2021
medline: 28 11 2021
Statut: epublish

Résumé

We have recently shown that a combined solution containing alpha-ketoglutarate (aKG) and 5-hydroxymethyl-furfural (5-HMF) might have anti-tumoral potential due to its antioxidative activities. The question arises if these substances have caspase-3- and apoptosis-activating effects on the cell proliferation in Jurkat and HF-SAR cells. Antioxidative capacity of several combined aKG + 5-HMF solution was estimated by cigarette smoke radical oxidized proteins of fetal calf serum (FCS) using the estimation of carbonylated proteins. The usage of 500 µg/mL aKG + 166.7 µg/mL 5-HMF showed the best antioxidative capacity to inhibit protein modification of more than 50% compared to control measurement. A Jurkat cell line and human fibroblasts (HF-SAR) were cultivated in the absence or presence of combined AKG + 5-HMF solutions between 0 µg/mL aKG + 0 µg/mL 5-HMF and different concentrations of 500 µg/mL aKG + 166.7 µg/mL 5-HMF. Aliquots of Jurkat cells were tested for cell proliferation, mitochondrial activity, caspase activity, apoptotic cells and of the carbonylated protein content as marker of oxidized proteins in cell lysates after 24, 48, and 72 h of incubation. The combined solutions of aKG + 5-HMF were shown to cause a reduction in Jurkat cell growth that was dependent on the dose and incubation time, with the greatest reductions using 500 µg/mL aKG + 166.7 µg/mL 5-HMF after 24 h of incubation compared to 24 h with the control (22,832 cells vs. 32,537 cells), as well as after 48 h (21,243 vs. 52,123 cells) and after 72 h (23,224 cells). Cell growth was totally inhibited by the 500 µg/mL AKG + 166.7 µg/mL solution between 0 and 72 h of incubation compared to 0 h of incubation for the control. The mitochondrial activity measurements supported the data on cell growth in Jurkat cells: The highest concentration of 500 µg/mL aKG + 166.7 µg/mL 5-HMF was able to reduce the mitochondrial activity over 24 h (58.9%), 48 h (28.7%), and 72 h (9.9%) of incubation with Jurkat cells compared not only to the control incubation, but also to the concentrations of 500 µg/mL aKG + 166.7 µg/mL 5-HMF or 375 µg/mL aKG 125 µg/mL 5-HMF, which were able to significantly reduce the mitochondrial activity after 48 h (28.7% or 35.1%) and 72 h (9.9% or 18.2%) compared to 24 h with the control (100%). A slight increase in cell proliferation was found in HF-SAR using the highest concentration (500 µg/mL aKG + 166.7 µg/mL 5-HMF) between 0 h and 72 h incubation of 140%, while no significant differences were found in the mitochondrial activity of HF-SAR in the absence or presence of several combined aKG + 5-HMF solutions. The solutions with 500 µg/mL aKG + 166.7 µg/mL 5-HMF or 250 µg/mL aKG + 83.3 µg/mL 5-HMF showed a significantly higher caspase activity (51.6% or 13.5%) compared to the control (2.9%) in addition to a higher apoptosis rate (63.2% or 31.4% vs. control: 14.9%). Cell lysate carbonylated proteins were significantly higher in Jurkat cells compared to HF-SAR cells (11.10 vs. 2.2 nmol/mg). About 72 h incubation of Jurkat cells with 500 µg/mL aKG + 166.7 µg/mL 5-HMF or 250 µg/mL aKG + 83.3 µg/mL 5-HMF reduced significantly the carbonylated protein content down to 5.55 or 7.44 nmol/mg whereas only the 500 µg/mL aKG + 166.7 µg/mL 5-HMF solution showed a significant reduction of carbonylated proteins of HF-SAR (1.73 nmol/mg).

Identifiants

pubmed: 34829675
pii: antiox10111804
doi: 10.3390/antiox10111804
pmc: PMC8614925
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Bioengineered. 2021 Dec;12(1):5323-5333
pubmed: 34499008
Cancer Metab. 2014 Mar 10;2(1):4
pubmed: 24612826
Int J Vitam Nutr Res. 2021 Jan;91(1-2):63-68
pubmed: 31411126
Oncogene. 2016 Jul 14;35(28):3619-25
pubmed: 26592449
Methods Enzymol. 1994;233:346-57
pubmed: 8015469
J Mater Sci Mater Med. 2007 Jun;18(6):1247-52
pubmed: 17277986
Free Radic Res. 2004 May;38(5):509-16
pubmed: 15293559
Int J Mol Sci. 2020 Dec 10;21(24):
pubmed: 33321940
Cancer Res. 2003 Dec 15;63(24):8670-3
pubmed: 14695179
Cell Rep. 2014 Jun 12;7(5):1679-1690
pubmed: 24857658
Biochem Pharmacol. 2001 Jan 15;61(2):227-35
pubmed: 11163337
Chem Cent J. 2018 Apr 4;12(1):35
pubmed: 29619623
Nat Rev Cancer. 2020 Dec;20(12):710-726
pubmed: 33087883
Biosci Biotechnol Biochem. 2020 Nov;84(11):2374-2384
pubmed: 32674671
Asian Pac J Cancer Prev. 2019 Jan 25;20(1):185-192
pubmed: 30678430
Cancer Cell. 2010 Mar 16;17(3):225-34
pubmed: 20171147
Front Physiol. 2012 Sep 14;3:369
pubmed: 23049513
Antioxidants (Basel). 2021 Sep 21;10(9):
pubmed: 34573133
Cold Spring Harb Symp Quant Biol. 2011;76:335-45
pubmed: 22089927
Biochem Biophys Res Commun. 2011 Mar 4;406(1):20-4
pubmed: 21281600
Phytother Res. 2016 May;30(5):754-67
pubmed: 26890810
Cancer Biol Ther. 2019;20(3):252-260
pubmed: 30289354
J Agric Food Chem. 2013 Nov 6;61(44):10604-11
pubmed: 24107143
Biochem Biophys Res Commun. 2012 Jan 6;417(1):446-50
pubmed: 22166196
Biochem J. 1998 Apr 15;331 ( Pt 2):599-606
pubmed: 9531503
Front Physiol. 2019 Jul 24;10:931
pubmed: 31396101

Auteurs

Joachim Greilberger (J)

Division of Physiological Chemistry, Otto Loewi Research, Medical University of Graz, 8010 Graz, Austria.
Schwarzl Medical Center, Institute of Scientific Laboratory, 8053 Graz, Austria.

Ralf Herwig (R)

German Medical Center, Department of Urology Surgery, Dubai 665664, United Arab Emirates.
Men's Health Clinic, 80337 Munich, Germany.

Michaela Greilberger (M)

Schwarzl Medical Center, Institute of Scientific Laboratory, 8053 Graz, Austria.

Philipp Stiegler (P)

Division of Transplantation Surgery, Medical University of Graz, 8010 Graz, Austria.

Reinhold Wintersteiger (R)

Department of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, University of Graz, 8010 Graz, Austria.

Classifications MeSH